For people whose advanced breast cancer has outlasted one round of hormone-blocking treatment, the next step has often meant choosing among options that carry a short window before the disease moves again. On Nov. 16, the Food and Drug Administration approved a once-daily pill, giredestrant, sold as Wilserdly, for a specific group of those patients. In the trial behind the approval, the pill combined with everolimus held the cancer in check for a median of 10 months, against 5.5 months for the comparison treatment.
Read next on Morning Overview: California’s Long Valley supervolcano is quietly sinking, its biggest drop on record
The approval is narrow, and the details of who qualifies matter as much as the topline result.
Who the approval covers
The Oncology Nursing Society’s summary of the FDA announcement gives the indication: giredestrant in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The ESR1 mutation must be identified by an FDA-authorized test, and the disease must have recurred during or after endocrine-based adjuvant therapy, or progressed on at least one endocrine-based regimen in the metastatic setting.
FDA also authorized a companion diagnostic, FoundationOne Liquid CDx, to identify the ESR1 variants. The agency approved the application four weeks ahead of its goal date, and the review ran under Project Orbis with Health Canada and Israel’s Ministry of Health.
The dose is 30 mg taken orally once daily, with or without food, until the disease progresses or toxicity becomes unacceptable, with everolimus dosed according to its own prescribing information.
The evERA trial and its numbers
OncLive reports that the approval rests on evERA Breast Cancer (NCT05306340), a randomized, open-label, multicenter study of 373 patients, 207 of whom had ESR1-mutated tumors. Patients received giredestrant plus everolimus or physician’s choice of endocrine therapy, also with everolimus. Per the Healio report, the physician’s-choice options were exemestane, fulvestrant or tamoxifen.
In the ESR1-mutated group, median progression-free survival was 10 months with giredestrant plus everolimus and 5.5 months with the comparator, a hazard ratio of 0.38 (95% confidence interval 0.27 to 0.54, P below 0.0001). Objective response rates were 27% and 14%. Progression-free survival was the trial’s primary endpoint, assessed by investigators.
Ten months versus 5.5 months is about 1.8 times as long, which fits “nearly doubled,” but the measure is time until the cancer progressed, not survival. Overall survival data were immature at the time of the analysis, The ASCO Post notes. AJMC reports a trend toward benefit, with a hazard ratio of 0.62 (95% confidence interval 0.38 to 1.02) in the ESR1-mutated group, an interval that reaches 1.02 and so does not settle the question.
In the full trial population, regardless of ESR1 status, median progression-free survival was 8.8 months against 5.5 months, a hazard ratio of 0.56, per OncLive and AJMC. The approval, though, covers only the ESR1-mutated population.
Side effects and warnings in the label
The most common adverse reactions, in at least 20% of patients, were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea, according to the FDA summary relayed by ONS. Common laboratory abnormalities included decreased hemoglobin, lymphocytes, white blood cells, neutrophils, platelets, calcium, potassium and sodium, and increased AST, ALT and creatinine. The prescribing information carries warnings for bradycardia and embryo-fetal toxicity. Both arms of the trial received everolimus.
The label carries practical instructions too. AJMC reports that patients who could become pregnant need effective nonhormonal contraception during treatment and for 2 weeks after the last dose, that the same applies to male patients with partners of reproductive potential, and that grapefruit and strong CYP3A inhibitors or inducers should be avoided.
Why ESR1 matters, and what the companies said
Healio states that ESR1 mutations are present in fewer than 5% of patients at the start of treatment but turn up in about 40% of those whose disease progresses, and that such tumors resist aromatase inhibitors yet have shown sensitivity to selective estrogen receptor degraders, the class giredestrant belongs to. Targeted Oncology describes everolimus as an oral mTOR inhibitor, and quotes lead investigator Erica L. Mayer of Dana-Farber Cancer Institute saying the combination may be a new all-oral option after CDK4/6 inhibitor therapy.
Healio attributes to Mayer, via a manufacturer press release, the statement that “Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices,” and describes the regimen as offering “prolonged disease control through a fully oral therapeutic option.” Targeted Oncology quotes her on the trial data: “Consistent benefit with this regimen was seen across key subgroups.”
Genentech’s Levi Garraway said that “the development of resistance to endocrine therapy remains a substantial challenge,” as quoted by AJMC. The company said the drug should be available in the United States in the coming weeks, and AJMC adds that a separate adjuvant application, based on the lidERA trial, has a decision date of Nov. 30, 2026. Neither coverage gives a price. Whether the 10-month median translates into longer survival is the question the immature overall-survival data cannot yet answer.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Czech Skyfox jets could become Ukraine’s cheap answer to Shahed attack drones
- A windstorm slammed western Washington, blocking I-5 and knocking out power for thousands
- Tesla’s Cybercab has already crashed 8 times, and the worst one came at highway speed
- Hidden wear was found inside a New Jersey nuclear reactor during its outage